NEW YORK (GenomeWeb News) – MolecularMD said today it has secured the rights to commercialize IP surrounding fibroblast growth factor receptor 2 activating mutations for diagnostic, prognostic, and predictive purposes in human endometrial cancer.
Rights to the IP are jointly held by Washington University in St. Louis and the Translational Genomics Research Institute.
Activating mutations in FGFR2 have been identified in 10 percent of primary uterine tumors that have been studied, the Portland, Ore.-based MolecularMD, said, adding endometrial carcinoma is the second leading cause of gynecologic cancer mortality in the developed world. In the US, an estimated 47,000 new cases were diagnosed in 2012, with 8,000 deaths.
Several therapies that target mutant FGFR2 are under development, and knowledge about a patient's FGFR2 status could aid in identifying new therapies and improve the survival of patients, MolecularMD said.
Financial terms of the deal were not disclosed.
Today's announcement follows an agreement at the start of the year in which MolecularMD licensed a genetic marker, LKB1, to develop diagnostic assays for non-small cell lung cancer.